Sativex Expected To Be Approved For Treatment Of MS
News: UK-based GW Pharmaceuticals' cannabis-derived drug Sativex (nabiximols) is likely to be approved for medical purposes in Finland, YLE has reported. National pharmaceutical agency Fimea's decision on Sativex for the treatment of spasticity associated with multiple sclerosis is expected in the next few weeks. If it is approved, the drug will be available in Finland upon prescription from a doctor on case-by-case basis. Sativex, which has already been approved in Sweden, is believed to provide several benefits, including relief from pain and stimulation of appetite.